Greenberg Bladder Cancer Institute; Johns Hopkins Medicine
Dr. Jean Hoffman-Censits is Assistant Professor of Medical Oncology and Urology at the Johns Hopkins University School of Medicine. Her research interests have focused on development of novel therapeutics for urothelial cancers. Work from her collaborations led to the first FDA approval of systemic immunotherapy for urothelial cancer, supported accelerated aMVAC as a standard preoperative regimen, and helped define biomarkers of chemotherapy response. She was integral in the success of the first multicenter trial of preoperative chemotherapy in upper tract urothelial cancer, and is leading a Phase III neoadjuvant chemo immunotherapy trial in the cooperative groups. She continues to develop novel trials for bladder, upper tract, as well as small cell bladder cancers.
She has long been interested in understanding and improving the inferior clinical outcomes of patients with less common presentations of bladder and urothelial cancers, including those with variant histology, upper tract location, and women with bladder cancer. She was thrilled to join the Johns Hopkins Greenberg Bladder Cancer Institute to lead and establish research initiatives for these rare populations.
Dr. Hoffman-Censits earned her medical degree at the The Sidney Kimmel Medical College at Thomas Jefferson University, where she completed internal medicine residency and chief residency. She completed her oncology training at Fox Chase Cancer Center, then returned to Jefferson as a genitourinary medical oncologist, leading their multidisciplinary GU oncology clinic. She joined the Johns Hopkins Greenberg Bladder Cancer Institute in 2018 as the co-leader of the Women’s Bladder Cancer program and Upper Tract Multidisciplinary Clinic.
AbbVie, genentech, Sanofi, GSK, UCB (Individual(s) Involved: Self; Clinical Condition: Oncology): Other Financial or Material Support, Research Support; Astra-Zeneca (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Foundation Medicine (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Genentech/Roche, Seattle Genetics, Amgen, Eli Lilly, Five Prime, Merck, BMS, Taiho, Astellas, Gritstone, Pieris, Daiichi Sankyo, Zymeworks, QED, Foundation Medicine, Tempus, Guardant Health, Archer, Natera (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Uro-gen (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant
Wednesday, March 9, 2022
12:50 PM – 3:20 PM
Wednesday, March 9, 2022
1:55 PM – 2:02 PM
Wednesday, March 9, 2022
2:09 PM – 2:15 PM
Wednesday, March 9, 2022
2:35 PM – 3:20 PM
Wednesday, September 28, 2022
1:10 PM – 3:05 PM
Wednesday, September 28, 2022
1:22 PM – 1:29 PM
Wednesday, September 28, 2022
1:29 PM – 1:35 PM
Wednesday, September 28, 2022
2:40 PM – 3:05 PM